Key Points
- Director Michael Beindorff sold 12,607 shares at an average price of $6.42 for a total of $80,936.94, reducing his ownership by 22.35% to 43,806 shares, as disclosed in an SEC Form 4.
- LifeVantage reported quarterly EPS of $0.18 (beating the $0.17 estimate) but missed on revenue at $47.56 million versus $54.74 million, and set FY2026 guidance of 1.000–1.150 EPS.
- The company declared a quarterly dividend of $0.045 per share (annualized $0.18), implying a 2.8% yield, with an ex-dividend date of December 1 and payment on December 15.
Lifevantage Corporation (NASDAQ:LFVN - Get Free Report) Director Michael Beindorff sold 12,607 shares of the company's stock in a transaction dated Wednesday, November 19th. The shares were sold at an average price of $6.42, for a total value of $80,936.94. Following the sale, the director owned 43,806 shares in the company, valued at approximately $281,234.52. This represents a 22.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Lifevantage Trading Up 1.9%
Shares of Lifevantage stock traded up $0.12 on Friday, reaching $6.43. The stock had a trading volume of 138,778 shares, compared to its average volume of 187,954. The business's 50 day moving average is $8.61 and its two-hundred day moving average is $11.36. The company has a market cap of $81.67 million, a P/E ratio of 8.69 and a beta of 0.22. Lifevantage Corporation has a 1 year low of $5.98 and a 1 year high of $27.38.
Lifevantage (NASDAQ:LFVN - Get Free Report) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.17 by $0.01. Lifevantage had a return on equity of 33.75% and a net margin of 4.29%.The company had revenue of $47.56 million during the quarter, compared to analyst estimates of $54.74 million. Lifevantage has set its FY 2026 guidance at 1.000-1.150 EPS.
Lifevantage Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Monday, December 15th. Shareholders of record on Monday, December 1st will be paid a dividend of $0.045 per share. The ex-dividend date of this dividend is Monday, December 1st. This represents a $0.18 annualized dividend and a yield of 2.8%. Lifevantage's payout ratio is 23.38%.
Hedge Funds Weigh In On Lifevantage
A number of institutional investors have recently bought and sold shares of LFVN. Capital Management Corp VA lifted its position in Lifevantage by 63.0% during the third quarter. Capital Management Corp VA now owns 2,064,176 shares of the company's stock valued at $20,084,000 after buying an additional 798,066 shares during the period. Driehaus Capital Management LLC bought a new position in shares of Lifevantage in the 1st quarter worth approximately $6,701,000. Wasatch Advisors LP grew its position in shares of Lifevantage by 6.6% during the 2nd quarter. Wasatch Advisors LP now owns 446,341 shares of the company's stock valued at $5,838,000 after acquiring an additional 27,765 shares during the period. Acadian Asset Management LLC raised its holdings in Lifevantage by 47.3% during the first quarter. Acadian Asset Management LLC now owns 291,700 shares of the company's stock valued at $4,248,000 after acquiring an additional 93,661 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Lifevantage by 106.1% in the second quarter. Geode Capital Management LLC now owns 245,332 shares of the company's stock worth $3,210,000 after acquiring an additional 126,274 shares during the period. 35.32% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of brokerages recently weighed in on LFVN. Wall Street Zen cut Lifevantage from a "buy" rating to a "hold" rating in a report on Saturday, November 8th. Weiss Ratings reiterated a "hold (c)" rating on shares of Lifevantage in a research report on Monday. Finally, Lake Street Capital reissued a "buy" rating and set a $12.00 price target on shares of Lifevantage in a research note on Wednesday, November 5th. Two research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $23.50.
Check Out Our Latest Research Report on LFVN
Lifevantage Company Profile
(
Get Free Report)
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
